Skip to content
Next results · Q4 2026Projected

Mar 22, after the close

Mon, Mar 22, 2027in 125 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 10 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$11.65M
Revenue, change from a year earlier: Q3 2026 −6.1%, Q2 2026 −84.6%, Q1 2026 −16.5%, Q4 2025 −21.4%
Net income
-$46.76M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Results day

Typical moveA typical move of 12.8% either way

Up after 2 of 4, down after 2.

The stock’s move from the last close before each release to the first close after it, over the last 4 releases. Largest: −15.2% after Q2 2026.

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

When it reports

Usual day
Thursday
6 of its last 8
Session
after the close
After quarter end
38 to 72 days
10-Q filed
38 to 44 days
over its last 8
10-K filed
72 to 89 days
over its last 8

Based on 8 prior 10-K filings.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR